Oak Street Health, Inc. (NYSE:OSH – Get Rating) insider Geoffrey M. Price sold 40,000 shares of the stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $27.97, for a total transaction of $1,118,800.00. Following the transaction, the insider now owns 1,543,270 shares in the company, valued at approximately $43,165,261.90. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Oak Street Health Price Performance
Shares of NYSE:OSH opened at $29.00 on Friday. The company has a market cap of $6.99 billion, a price-to-earnings ratio of -14.65 and a beta of 2.21. The company has a debt-to-equity ratio of 16.10, a current ratio of 1.79 and a quick ratio of 1.79. The firm has a 50 day simple moving average of $20.15 and a 200 day simple moving average of $20.43. Oak Street Health, Inc. has a one year low of $13.29 and a one year high of $65.22.
Oak Street Health (NYSE:OSH – Get Rating) last issued its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.04). The company had revenue of $513.80 million during the quarter, compared to the consensus estimate of $506.82 million. Oak Street Health had a negative net margin of 26.82% and a negative return on equity of 413.94%. Oak Street Health’s revenue for the quarter was up 73.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.29) EPS. Research analysts predict that Oak Street Health, Inc. will post -2.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Oak Street Health
Analyst Ratings Changes
A number of brokerages have issued reports on OSH. Bank of America lowered shares of Oak Street Health from a “buy” rating to an “underperform” rating and decreased their target price for the stock from $26.00 to $18.00 in a research report on Wednesday, June 15th. Barclays increased their target price on shares of Oak Street Health from $27.00 to $31.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 19th. UBS Group assumed coverage on shares of Oak Street Health in a research report on Wednesday, April 20th. They set a “neutral” rating and a $26.00 price target on the stock. Argus assumed coverage on shares of Oak Street Health in a research report on Tuesday. They set a “hold” rating on the stock. Finally, Stifel Nicolaus increased their price target on shares of Oak Street Health from $25.00 to $35.00 in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, Oak Street Health has a consensus rating of “Moderate Buy” and a consensus price target of $34.81.
About Oak Street Health
Oak Street Health, Inc, together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2021, it operated 129 centers in 19 states, including Illinois, Michigan, Pennsylvania, Ohio, and Texas.
- Get a free copy of the StockNews.com research report on Oak Street Health (OSH)
- Wingstop And Hershey Are Two Food Stocks Overcoming Inflation
- Can International Business Machines Recover After Its Sell-Off?
- Ford Stock Rallies As EV Strategy Takes Center Stage
- Should High Yield Altria Be In Your Portfolio?
- Is Keurig-Dr. Pepper A Value Worth Buying?
Receive News & Ratings for Oak Street Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oak Street Health and related companies with MarketBeat.com's FREE daily email newsletter.